HUT53901A - Process for producing azelastin salts of improved solubility and pharmaceutical compositions containing them - Google Patents

Process for producing azelastin salts of improved solubility and pharmaceutical compositions containing them

Info

Publication number
HUT53901A
HUT53901A HU902678A HU267890A HUT53901A HU T53901 A HUT53901 A HU T53901A HU 902678 A HU902678 A HU 902678A HU 267890 A HU267890 A HU 267890A HU T53901 A HUT53901 A HU T53901A
Authority
HU
Hungary
Prior art keywords
salts
improved solubility
azelastin
producing
pharmaceutical compositions
Prior art date
Application number
HU902678A
Other languages
English (en)
Other versions
HU902678D0 (en
HU206110B (en
Inventor
Helmut Hettche
Reinhard Muckenschnabel
Gerhard Scheffler
Ilona Fleischauer
Wolfgang Morick
Original Assignee
Asta Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag filed Critical Asta Pharma Ag
Publication of HU902678D0 publication Critical patent/HU902678D0/hu
Publication of HUT53901A publication Critical patent/HUT53901A/hu
Publication of HU206110B publication Critical patent/HU206110B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU902678A 1989-05-05 1990-05-04 Process for producing azelatine salts with improved solubility and pharmaceutical compositions comprising same HU206110B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3914859 1989-05-05

Publications (3)

Publication Number Publication Date
HU902678D0 HU902678D0 (en) 1990-09-28
HUT53901A true HUT53901A (en) 1990-12-28
HU206110B HU206110B (en) 1992-08-28

Family

ID=6380164

Family Applications (1)

Application Number Title Priority Date Filing Date
HU902678A HU206110B (en) 1989-05-05 1990-05-04 Process for producing azelatine salts with improved solubility and pharmaceutical compositions comprising same

Country Status (17)

Country Link
US (4) US5086050A (hu)
EP (1) EP0396069B1 (hu)
JP (1) JPH02295987A (hu)
AT (1) ATE107643T1 (hu)
AU (1) AU622022B2 (hu)
CA (1) CA2016089C (hu)
DD (1) DD294254A5 (hu)
DE (2) DE59006184D1 (hu)
DK (1) DK0396069T3 (hu)
ES (1) ES2055216T3 (hu)
FI (1) FI902244A0 (hu)
HU (1) HU206110B (hu)
IE (1) IE63662B1 (hu)
NO (1) NO901985L (hu)
NZ (1) NZ233546A (hu)
PT (1) PT93946B (hu)
YU (1) YU86390A (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
JPH04198180A (ja) * 1990-11-28 1992-07-17 Eezai Kagaku Kk ベンジルフタラゾン誘導体の製造方法
US5296472A (en) * 1991-12-05 1994-03-22 Vyrex Corporation Methods for delipidation of skin and cerumen removal
JP4138910B2 (ja) 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7694694B2 (en) * 2004-05-10 2010-04-13 The Aerospace Corporation Phase-change valve apparatuses
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
DK2522365T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
DK2697662T3 (en) 2011-04-13 2018-07-30 Codexis Inc BIOCATALYTIC PROCEDURE FOR PREPARING ESLICARBAZEPIN AND ANALOGUES THEREOF
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH572914A5 (hu) * 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
ATE49205T1 (de) * 1984-09-14 1990-01-15 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.
EP0222191B1 (de) * 1985-11-11 1991-01-30 ASTA Pharma AG 4-Benzyl-1-(2H)-phthalazinon-Derivate
JPH0667844B2 (ja) * 1987-03-06 1994-08-31 エーザイ株式会社 虚血性心疾患の治療・予防剤
EP0289939A1 (de) * 1987-05-08 1988-11-09 ASTA Pharma AG Neue 4-Benzyl-1-(2H)-phthalazinon-Derivate mit einem Aminosäurerest
PT88984B (pt) * 1987-11-13 1993-01-29 Asta Medica Ag Processo para a preparação de embonato de azelastina e de composições earmacâutxcas que 0 contêm como ingrediente activo
US5232919A (en) * 1987-11-13 1993-08-03 Asta Pharma Aktiengesellschaft Azelastine embonate and compositions which contain it
EP0316639B1 (de) * 1987-11-13 1994-06-08 ASTA Medica Aktiengesellschaft Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten
JP2794021B2 (ja) * 1988-11-02 1998-09-03 エーザイ株式会社 アゼラスチン或いはその塩類含有経皮適用製剤

Also Published As

Publication number Publication date
US5998403A (en) 1999-12-07
AU622022B2 (en) 1992-03-26
AU5473690A (en) 1990-11-08
EP0396069A1 (de) 1990-11-07
DK0396069T3 (da) 1994-07-25
US5086050A (en) 1992-02-04
FI902244A0 (fi) 1990-05-04
EP0396069B1 (de) 1994-06-22
CA2016089C (en) 1998-12-01
PT93946A (pt) 1991-01-08
IE901639L (en) 1990-11-05
PT93946B (pt) 1996-11-29
HU902678D0 (en) 1990-09-28
YU86390A (en) 1992-05-28
DE59006184D1 (de) 1994-07-28
DD294254A5 (de) 1991-09-26
ATE107643T1 (de) 1994-07-15
IE63662B1 (en) 1995-05-31
NO901985D0 (no) 1990-05-04
HU206110B (en) 1992-08-28
US6017909A (en) 2000-01-25
DE4013696A1 (de) 1990-11-08
NZ233546A (en) 1991-09-25
NO901985L (no) 1990-11-06
US5859003A (en) 1999-01-12
JPH02295987A (ja) 1990-12-06
CA2016089A1 (en) 1990-11-05
ES2055216T3 (es) 1994-08-16

Similar Documents

Publication Publication Date Title
HUT53901A (en) Process for producing azelastin salts of improved solubility and pharmaceutical compositions containing them
ES482330A1 (es) Un procedimiento para producir derivados de acido (dl)-16- fenoxi, y 16-fenoxi-sustituido-9-ceto-prostatrienoico.
ES449162A1 (es) Un procedimiento para la preparacion de un compuesto racemi-co u 8r-antimerico.
MY107657A (en) Process for the production of carboxylic acid anhydrides.
DE3570437D1 (en) 1-hydroxy-1,1-diphosphonic-acid derivatives, process for their preparation and pharmaceutical preparations, especially for the treatment of bone tumours
IL112020A0 (en) Arylacetic acid derivatives, their preparation and their use as fungicides
GR3002341T3 (en) Process for preparing high purity dermatan-sulphate, and pharmaceutical compositions wich contain it
IL152348A0 (en) Oxidation process for preparing the intermediate 6.alpha.-difluoro-11.beta., 17.alpha.-dihydroxy-16.alpha.-methyl-androst-1,4-dien-3-one 17.beta.-carboxylic acid
GR3030576T3 (en) Solid compositions containing amine oxide-maleic acid salts
KR100214903B1 (en) Process for producing aminomethanephosphonic acid and aminomethylphosphinic acids
HUT40793A (en) Process for preparing hexene-carboxylic acid derivatives
JPS56121436A (en) Formula stock feed
ES8405370A1 (es) Un procedimiento para preparar diasteredisomeros derivados de pirrolidina
ES8403106A1 (es) Procedimiento para la preparacion de 3-(10,11-dihidro-5h-dibenzo-a,d-ciclohepten-5-iliden-n,n-dimetil-1-propanamin-n-o- xido dihidratado.
UA26982A1 (uk) Похідhі малоhової кислоти, які проявляють властивості іhгібітору росту рослиh
GEP19971045B (en) Method for production of derivatives of acrylic acid and its stereoisomers
ES2018745A6 (es) Procedimiento para la obtencion de n-carboximetilglicina y sus sales.
IL145017A0 (en) METHOD FOR PRODUCING 4,4-DIMETHYL-3β-HYDROXYPREGNA-8,14-DIENE-21 -CARBOXYLIC ACID ESTERS AND INTERMEDIATE PRODUCTS OBTAINED BY SAID METHOD

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: VIATRIS GMBH & CO. KG, DE

HC9A Change of name, address

Owner name: MEDA PHARMA GMBH & CO. KG, DE

Free format text: FORMER OWNER(S): ASTA MEDICA AG., DE; ASTA MEDICA HEALTH PRODUCTS GMBH & CO. KG, DE; VIATRIS GMBH &CO. KG, DE; VIATRIS GMBH & CO. KG, DE